Zivko, Cristina
Sagar, Ram http://orcid.org/0000-0002-4297-2639
Xydia, Ariadni
Lopez-Montes, Alejandro
Mintzer, Jacobo
Rosenberg, Paul B.
Shade, David M.
Porsteinsson, Anton P. http://orcid.org/0000-0002-0166-1738
Lyketsos, Constantine G. http://orcid.org/0000-0003-3827-4720
Mahairaki, Vasiliki http://orcid.org/0000-0001-6281-5895
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R21 AG067016, R21 AG067016, R21 AG067016)
The Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease at Johns Hopkins
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Article History
Received: 5 November 2023
Revised: 16 May 2024
Accepted: 28 May 2024
First Online: 5 June 2024
Competing interests
: Dr. Lyketsos has served or serves as consultant or advisor to Roche, Avanir, Karuna, Maplight, Axsome, GIA, GW Research Limited, Merck, EXCIVA GmbH, Otsuka, IntraCellular Therapies, Medesis. Dr. Porsteinsson reports personal fees from Acadia Pharmaceuticals, Athira, Biogen, Cognitive Research Corp, Eisai, Functional Neuromodulation, IQVIA, Lundbeck, Medscape, Novartis, ONO Pharmaceuticals, and Xenon; grants to his institution from Alector, Athira, Biogen, Cassava, Eisai, Eli Lilly, Genentech/Roche, Vaccinex, NIA, NIMH, and DOD. Dr. Rosenberg has received research grants from the National Institutes of Aging, Alzheimer’s Clinical Trials Consortium, Richman Family Precision Medicine Center of Excellence on Alzheimer’s Disease, Eisai, Functional Neuromodulation, and Lilly; honoraria from GLG, Leerink, Cerevel, Cerevance, Bioxcel, Sunovion, Acadia, Medalink, Novo Nordisk, Noble Insights, TwoLabs, Otsuka, Lundbeck, Acadia, MedaCorp, ExpertConnect, HMP Global, Sinaptica, Synaptogenix, and Neurology Week. Dr. Jacobo Mintzer is a consultant and Governance Committee Member for AARP’s Global Council on Brain Health (GCBH). He is a consultant for ACADIA, AiOmed, the Alliance for Aging Research, Exciva, Genentech (affiliate of F. Hoffmann-La Roche Ltd), Lundbeck, Otsuka/Avanir, and Praxis Bioresearch. Dr. Mintzer is a Steering Committee Member for the Alzheimer’s Clinical Trials Consortium (ACTC), and the Alzheimer’s Therapeutic Research Institute (ATRI). He is a Board Member for the Alzheimer’s Association, SC Chapter and the Technology Accelerator Company (TAC) as well as an Association Member of the International Psychogeriatric Association (IPA). Dr. Mintzer is a stockholder and the VP for Clinical Affairs for NeuroQuest, a majority owner of Biopharma Connex, and a majority partner for Recruitment Partners. He is a member of the Nabilone for Agitation Blinded Intervention Trial (NAB-IT) and the Cannabinoid Liquid Medication Intervention Trial (CALM-IT) Data Safety and Monitoring Boards (DSMB). Finally, he is receiving support for specific clinical trials from the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation (ADDF), Cerevel Therapeutics LLC, Cognition Therapeutics, Inc., Eisai Inc., the GHR Foundation, the National Endowment for the Arts (NEA), the National Institute on Aging (NIA), the National Institute of Health (NIH), Suven Life Sciences Ltd., and Vivoryon Therapeutics.
: Induced Human iPSCs used in this project have been generated from peripheral blood monocytes obtained upon fully informed consent from human subjects as outlined by the JHMI eIRB-approved research study application (NA_00045104) and consent process. All experiments were conducted according to regulations governing the use of human stem cell lines in biomedical research.